The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the ...

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to ...

Microsatellite instability (MSI), which results from defects in the DNA mismatch repair system, is an important biomarker in colorectal cancer. While the MSI-high (MSI-H) status predicts response to ...

NEW YORK - Researchers led by Ludwig Chicago Co-director Ralph Weichselbaum report in the current issue of Nature that high ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...